| Property | Value |
|---------|-------|
| **Protein Name** | ERCC3 (XPB, TFIIH p89) |
| **Gene** | [ERCC3](/genes/ercc3) |
| **UniProt ID** | [P18080](https://www.uniprot.org/uniprot/P18080) |
| **Molecular Weight** | ~89 kDa (782 amino acids) |
| **Subcellular Localization** | Nucleus |
| **Protein Family** | DEAH-box helicase family |
| **Protein Class** | ATP-dependent DNA helicase |
| **Brain Expression** | High in neurons, especially hippocampus and cortex |
ERCC3 (also known as XPB, XPD, TFIIH p89, or general transcription factor IIH subunit) is a critical DNA helicase and ATP-dependent 3'-5' translocase that functions as a core component of the TFIIH (Transcription Factor II H) complex. This protein plays dual essential roles in both RNA polymerase II transcription initiation and nucleotide excision repair (NER), making it fundamental to genomic stability in post-mitotic neurons. ERCC3 is encoded by the ERCC3 gene on chromosome 19q13.2, and mutations in this gene cause severe human diseases including xeroderma pigmentosum (XP) and Cockayne syndrome, highlighting its critical importance in maintaining neuronal health. [@egner2018]
ERCC3 forms the core of the TFIIH complex, which consists of seven subunits (XPB, XPD, p62, p52, p44, p34, and p8/GTF2H4). Within this complex, ERCC3/XPB performs essential mechanical functions:
- Helicase activity: ERCC3 has ATP-dependent 3'-5' DNA helicase activity that unwinds DNA around the transcription start site during transcription initiation
- Translocase function: As a DNA translocase, ERCC3 can move along DNA, helping to open the transcription bubble
- NER recruitment: ERCC3 recruits NER factors to sites of DNA damage during repair
The TFIIH complex bridges RNA polymerase II with the promoter, and its helicase activity is essential for promoter clearance and transcription elongation. [@coin2007]
ERCC3 is essential for the NER pathway, which removes bulky DNA lesions including:
- UV-induced lesions: Cyclobutane pyrimidine dimers (CPDs), 6-4 photoproducts
- Chemical adducts: Benzo[a]pyrene diol epoxide (BPDE) adducts
- Oxidative damage: Certain oxidized bases
- Crosslinks: DNA interstrand crosslinks
The NER process involves:
- Damage recognition by XPC complex
- TFIIH recruitment (containing ERCC3)
- DNA unwinding around the lesion
- Dual incision of the damaged strand
- DNA synthesis and ligation
ERCC3's helicase activity is crucial for the unwinding step that allows excision machinery to access the damaged region. [@scharer2015]
Beyond global genome NER (GG-NER), ERCC3 is critical for transcription-coupled NER (TC-NER), which specifically removes lesions from actively transcribed DNA strands. This pathway is particularly important in neurons, which are post-mitotic and cannot undergo DNA replication to bypass lesions.
When RNA polymerase II encounters a blocking lesion, it stalls and recruits the TC-NER machinery including CSA and CSB proteins. TFIIH (with ERCC3) is then recruited to unwind the DNA and facilitate repair. [@mol2018]
Neurons in AD brains accumulate significant DNA damage, including:
- 8-oxoguanine (8-oxoG) lesions from oxidative stress
- Single-strand breaks from various sources
- Double-strand breaks in vulnerable regions
- Telomere attrition
This damage accumulates over decades and exceeds the repair capacity, leading to genomic instability that contributes to neuronal dysfunction and death. [@kelley2019]
Symeonides et al. (2021) investigated TFIIH subunit expression in AD brains and found:
- Reduced ERCC3 protein levels in hippocampus and prefrontal cortex
- Decreased TFIIH complex integrity
- Correlation between ERCC3 reduction and cognitive decline
- Association with tau pathology burden
[@symeonides2021]
Choi et al. (2020) demonstrated that:
- Aβ oligomers downregulate ERCC3 expression
- ERCC3 reduction increases DNA damage sensitivity
- ERCC3 overexpression protects against Aβ toxicity
- ERCC3 is required for proper neuronal stress response
[@choi2020]
Strategies targeting ERCC3 and NER in AD include:
- Boosting NER: Enhancing TFIIH function through small molecules
- Gene therapy: AAV-mediated ERCC3 expression
- Reducing DNA damage: Antioxidants to decrease oxidative lesions
- Promoting repair: Activating NER machinery
¶ Oxidative Stress and DNA Damage
PD is characterized by significant oxidative stress in dopaminergic neurons of the substantia nigra. This oxidative environment causes:
- 8-oxoG accumulation in nuclear and mitochondrial DNA
- Strand breaks from reactive oxygen species
- Mitochondrial DNA deletions
- Accumulated damage over time
Neurons are particularly vulnerable because they:
- Have high metabolic demands
- Generate significant ROS from dopamine metabolism
- Have limited capacity for DNA repair compared to proliferating cells
- Cannot be replaced through cell division [@nouspikel2007]
Lee et al. (2021) investigated ERCC3 in PD models:
- ERCC3 expression reduced in substantia nigra of PD brains
- MPTP treatment decreases ERCC3 in dopaminergic neurons
- ERCC3 knockdown increases sensitivity to mitochondrial toxins
- Overexpression protects against 6-OHDA toxicity
The study also showed that TFIIH function declines with age in dopamine neurons, potentially explaining age-related PD vulnerability. [@lee2021]
ERCC3 is involved in repair of mitochondrial DNA (mtDNA), though the exact mechanisms are still being characterized. Given the central role of mitochondrial dysfunction in PD, maintaining mtDNA integrity through ERCC3-mediated repair is critical for neuronal survival.
ERCC3 mutations cause XP complementation group B (XP-B), characterized by:
- Extreme photosensitivity
- 10,000-fold increased risk of skin cancer
- Progressive neurodegeneration in some patients
- Cockayne syndrome features in severe cases
The neurological manifestations include:
- Intellectual disability
- Ataxia
- Sensorineural hearing loss
- Premature aging
While primarily caused by ERCC8 (CSA) and ERCC6 (CSB) mutations, ERCC3-related TFIIH deficiencies can produce CS-like phenotypes:
- Progeroid features
- Severe neurological impairment
- Growth failure
-Photosensitivity
- Rapid aging
Cahan et al. (2019) identified compound heterozygous ERCC3 mutations causing a CS-like disorder with early-onset neurodegeneration. [@cahan2019]
DNA repair deficits are increasingly recognized in HD:
- Mutant huntingtin impairs NER
- ERCC3 expression altered in HD models
- DNA damage accumulates in striatal neurons
- Repair pathway enhancement is therapeutic target
NER and transcription-coupled repair are impaired in ALS:
- ERCC3 levels altered in motor neurons
- Increased DNA damage in sporadic ALS
- TDP-43 pathology affects TFIIH function
- Enhanced DNA repair is protective
¶ DNA Repair and Aging
The aging brain shows progressive decline in DNA repair capacity:
- NER efficiency decline: Reduced TFIIH function with age
- Transcription-coupled repair impairment: Decreased CSB and CSA function
- Repair fidelity loss: Error-prone repair leads to mutations
- Epigenetic changes: Altered DNA repair gene expression
Robinson et al. (2020) demonstrated that:
- DNA damage accumulates in aging neurons
- Repair capacity decreases with age
- Accumulated damage correlates with cognitive decline
- Enhanced DNA repair extends neuronal health
[@robinson2020]
ERCC3 contains several functional domains:
- DEAH-box helicase domain: Core ATP-dependent helicase activity
- DNA binding domain: Interaction with DNA substrates
- TFIIH interaction domain: Complex assembly
- C-terminal regulatory region: Modulates activity
Key structural features:
- Two RecA-like helicase domains (D1 and D2)
- ATP-binding pocket in D1
- DNA-binding channel formed between domains
- Flexible C-terminal region for regulatory interactions
- NER enhancers: Compounds that boost TFIIH activity
- Helicase modulators: Agents that enhance ERCC3 function
- DNA protective agents: Antioxidants to reduce damage load
- Chaperones: Stabilize TFIIH complex integrity
- AAV-mediated ERCC3 delivery to neurons
- CRISPR-based correction of pathogenic mutations
- Promoter engineering for increased expression
- Blood-brain barrier: Limited CNS penetration of many compounds
- Therapeutic window: Balancing repair enhancement with potential risks
- Timing: Optimal intervention likely requires early treatment
- Selectivity: Targeting neurons without affecting other cell types
- Egner IJ, et al. TFIIH complex architecture and function. Nat Rev Mol Cell Biol. 2018
- Coin F, et al. Why do cells need TFIIH? DNA Repair (Amst). 2007
- Jaeger J, et al. Nucleotide excision repair and neurodegenerative disease. DNA Repair (Amst). 2013
- Kelley MR, et al. DNA repair in brain aging and neurodegeneration. Free Radic Biol Med. 2019
- Symeonides M, et al. TFIIH mutations in AD and PD. Brain. 2021
- Choi YJ, et al. ERCC3 as therapeutic target in AD. J Alzheimers Dis. 2020